Regenerative Biologics
in Aesthetic
Medicine

PRP for androgenetic alopecia (AGA) has the strongest aesthetic biologic evidence base outside of wound healing — supported by 19+ RCTs and multiple systematic reviews demonstrating significant hair density and shaft diameter improvement vs. placebo. Mechanism centers on PDGF and IGF-1 stimulation of dermal papilla cells to prolong the anagen (growth) phase, combined with VEGF-driven perifollicular angiogenesis to restore the capillary supply that miniaturized follicles depend on.

Standard protocols call for 3–4 monthly injection sessions followed by maintenance every 3–6 months. PRP is best used as an adjunct to or amplifier of medical therapy (minoxidil, finasteride) rather than a standalone treatment for moderate-to-severe AGA — evidence consistently shows combination protocols outperform either approach alone. Exosomes represent an emerging alternative for patients who prefer to avoid the blood draw, with non-inferior efficacy signals in the first comparative RCT data.

Atrophic acne scarring — encompassing ice-pick, rolling, and boxcar scar subtypes — is driven by dermal collagen deficit following the inflammatory destruction of acne lesions. The biological target is fibroblast-mediated matrix restoration, making PRP mechanistically well-aligned. The combination of microneedling (physical disruption of fibrous scar bands and wound-healing cascade stimulation) with PRP (growth factor supply to the activated repair environment) produces additive outcomes documented in multiple split-face RCTs.

Evidence is particularly strong for rolling and superficial boxcar scars, where fibroblast-accessible dermis remains. Ice-pick scars have a more limited biologic response due to their deep, narrow geometry. Subcision (mechanical disruption of subcutaneous fibrous tethers) combined with PRP injection is the most effective protocol for rolling scars specifically. Exosome delivery post-microneedling is gaining evidence as an alternative or adjunct to PRP with a lower procedural barrier.

Alopecia areata is an autoimmune condition in which T-lymphocyte infiltration around the follicular bulge creates a localized immune attack on the hair follicle — distinct from the androgenic miniaturization mechanism of AGA. PRP’s immunomodulatory activity — through platelet-derived TGF-β1 and PDGF-mediated T-cell suppression — addresses the autoimmune mechanism more directly than simple growth factor stimulation, explaining the durability advantage observed over corticosteroid in RCT follow-up data.

Intralesional PRP injection at 3–4 week intervals targeting active patches is the established protocol. Response rates in patch-type alopecia areata are significantly better than in total alopecia areata, where the systemic immune burden exceeds local biologic intervention capacity. WJ-MSC injection has been described in case reports for refractory alopecia areata with promising immune-modulatory rationale, though controlled data is lacking.

The neck, décolletage, and dorsal hands are among the most photoaged body regions with the fewest effective conventional treatment options — too thin and delicate for most energy devices, and structurally different from facial skin in ways that limit filler approaches. Biologic injection is particularly suited to these regions: PRP mesotherapy (multiple small intradermal blebs at 1 cm spacing) provides diffuse growth factor delivery without creating planes of dissection that risk visible irregularity in thin skin.

Clinical series on neck and décolletage PRP report significant improvements in skin texture, crepiness, and hydration at 6 months — outcomes that are difficult to achieve with any conventional modality. Hand rejuvenation with PRP combined with HA filler (PRP to address skin quality, HA for tendon prominence) provides comprehensive improvement addressing the two primary aesthetic concerns of aged hands.

Hypertrophic scars and keloids represent a failure of the normal wound-healing resolution phase — in which TGF-β1 signaling drives fibroblast-to-myofibroblast transdifferentiation and excessive collagen deposition without appropriate apoptotic shutdown. Conventional treatment (corticosteroid injection, laser, silicone sheeting) addresses the symptom but not the underlying myofibroblast hyperactivation.

Amniotic membrane’s TSG-6 and IL-1Ra content directly inhibit the TGF-β1 signaling driving myofibroblast persistence — a mechanistically rational approach to scar prevention and treatment distinct from immune suppression with corticosteroid. Intralesional PRP at lower concentrations (paradoxically) shows anti-fibrotic activity through PDGF-mediated MMP upregulation and normalized matrix remodeling. Multiple prospective series now support both modalities as adjuncts to laser and other scar treatments, with the clearest evidence for prevention (post-surgical amniotic membrane coverage) rather than established keloid treatment.

Post-procedure recovery optimization is among the most immediately scalable biologic applications in aesthetic practice — applicable following ablative laser, chemical peel, microneedling, surgical facelift, and rhinoplasty. The biological rationale is straightforward: all of these procedures create controlled tissue injury to stimulate healing; biologics supply the growth factor reservoir that maximizes the healing response quality and speed.

For post-ablative laser, PRP applied immediately post-treatment and lyophilized amniotic membrane as wound coverage for the first 24–72 hours address re-epithelialization speed and PIH risk respectively. For surgical patients, PRP applied at closure reduces hematoma and accelerates tissue adherence. Topical exosome serums applied post-microneedling in the clinic and by patients at home for 3–5 days represent a practical “take-home biologic” protocol that extends the treatment effect beyond the office visit.

Striae distensae (stretch marks) represent permanent dermal scarring from rapid skin expansion exceeding the dermis’s mechanical tolerance — producing linear atrophic lesions with disrupted collagen, elastin, and fibrillin-1 architecture. Conventional treatment options are limited, with laser providing the strongest evidence for striae rubra (active, red) and modest improvement in striae alba (mature, white).

PRP combined with microneedling and fractional laser has been evaluated in several prospective series, with significant improvements in striae color, texture, and width reported in striae rubra at 3 months. Response in mature striae alba is more modest — consistent with the general principle that biologic treatments yield greater benefit when the repair process remains biologically active. Amniotic membrane-derived growth factors (EGF, TGF-β3, fibronectin) address the structural ECM deficit with a more differentiated profile than PRP alone.